Achieve Life Sciences (ACHV) financial statements
Net income was -$55M.
Free cash flow was -$49M.
The diluted share count rose 2053346% over the period (dilution).
Income statement
Fiscal years, from Achieve Life Sciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | — | — | — | — | — | — |
| Research and development | $286,000 | $3M | $6M | $10M | $7M | $24M | $30M | $16M | $23M | — |
| Selling, general and admin | $1M | $4M | $7M | $7M | $8M | $9M | $11M | $11M | $16M | — |
| Operating income | — | — | -$13M | -$17M | — | — | — | — | — | — |
| Interest expense | — | — | — | — | — | — | $2M | $3M | $2M | $819,000 |
| Pre-tax income | -$2M | -$14M | -$13M | -$16M | -$15M | -$33M | -$42M | -$30M | -$40M | -$55M |
| Income tax | $0 | — | — | — | — | — | — | — | — | — |
| Net income | -$1M | -$11M | -$13M | -$16M | -$15M | -$33M | -$42M | -$30M | -$40M | -$55M |
| EPS (diluted) | -$581.25 | -$22.07 | -$72.29 | -$39.76 | -$5.42 | -$4.08 | -$4.00 | -$1.50 | -$1.24 | -$1.25 |
| Diluted shares | 0M | 0M | 0M | 0M | 3M | 8M | 11M | 20M | 32M | 44M |
Balance sheet
Fiscal years, from Achieve Life Sciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $26M | $5M | $15M | $17M | $36M | $43M | $25M | $16M | $34M | $36M |
| Receivables | $478,000 | $9,000 | $7,000 | $8,000 | — | — | — | — | — | — |
| Total current assets | $18,000 | $6M | $16M | $17M | $37M | $45M | $27M | $17M | $36M | $40M |
| Property, plant and equipment | $258,000 | $59,000 | $35,000 | $57,000 | $42,000 | $15,000 | $4,000 | $13,000 | $8,000 | $3,000 |
| Goodwill | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M |
| Total assets | $4M | $10M | $19M | $21M | $40M | $48M | $30M | $19M | $39M | $42M |
| Total current liabilities | $3M | $2M | $3M | $3M | $3M | $5M | $22M | $21M | $7M | $9M |
| Total liabilities | $3M | $2M | $3M | $3M | $3M | $19M | $22M | $21M | $18M | $20M |
| Shareholders' equity | $610,000 | $16M | $16M | $18M | $37M | $28M | $8M | -$1M | $21M | $22M |
| Net debt | -$15,000 | -$5M | -$10M | -$17M | -$36M | -$43M | -$25M | -$16M | -$13M | -$21M |
Cash flow
Fiscal years, from Achieve Life Sciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$202,000 | -$9M | -$11M | -$15M | -$13M | -$29M | -$38M | -$24M | -$30M | -$49M |
| Capital spending | $46,000 | — | $46,000 | $53,000 | $17,000 | — | — | $21,000 | — | $3,000 |
| Free cash flow | -$248,000 | — | -$11M | -$15M | -$13M | — | — | -$24M | — | -$49M |
| Stock-based compensation | $2M | $348,000 | $854,000 | $1M | $1M | $2M | $3M | $3M | $5M | $9M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ACHV.
Open ACHV in InvestinglyQuestions
How much free cash flow does Achieve Life Sciences generate?
-$49M in fiscal 2025 (operating cash flow minus capital spending).
From Achieve Life Sciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.